Evidence map›Paper›PMID 42327254›Full record

ArticlebioRxiv : the preprint server for biology2026

Evaluating agentic AI for biological discovery in autonomous and copilot settings.

Shreya Johri, Erica Pimenta, Josephine Yates, Jingxin Fu, Erik L Bao, Hyeji Jun, Brendan Reardon, Sasha Bacot, Maha Shady, Doris Fu and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shreya JohriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-2388-3913
Erica PimentaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Josephine YatesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jingxin FuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Erik L BaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-6074-6766
Hyeji JunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brendan ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1716-5720
Sasha BacotDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Maha ShadyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Doris FuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wenbin MeiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sabrina Y CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eliezer Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0201-4444

Funding

Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate CancerP50CA272390 · NCI · DANA-FARBER CANCER INST · PI Steven P. Balk, Himisha Beltran · 2023 to 2026
$12.0M
Molecular origins and evolution to treatment resistance in genitourinary cancersR50CA265182 · NCI · DANA-FARBER CANCER INST · PI Jihye Park · 2022 to 2026
$1.7M
NCI NIH HHS P50 CA272390NCI NIH HHS R50 CA265182
6 · The paper itself

Abstract

Advances in large language models (LLMs)-based artificial intelligence (AI) agents have improved their ability to execute structured analytical workflows, including standard bioinformatic pipelines for biological discovery. However, computational biology rarely consists of deterministic pipeline execution alone. Biological datasets are heterogeneous and noisy, and meaningful discovery often requires open-ended hypothesis generation and iterative reasoning over multimodal evidence. These challenges are particularly evident in multi-omic studies, where paired molecular modalities and heterogeneous clinical contexts create both opportunities and obstacles for discovery. The extent to which emerging agentic AI systems can support or automate this mode of scientific discovery remains poorly understood. Here, we systematically evaluated the capabilities and limitations of agentic AI for biological discovery using multi-omic single cell datasets spanning 11 cancer types. We developed the Multistep Multimodal Multiomic Agentic (M3A) Framework to support LLM-driven reasoning over persistent multimodal data states and to capture agentic reasoning behavior in autonomous and human-AI copilot settings. Using this framework, we assessed AI agents across complementary tasks, including autonomous cell-type annotation, generation of falsifiable biological hypotheses from gene programs, and copilot experiments testing the effect of human involvement and domain expertise. We found that current AI agents are effective at broad, systemic exploration of complex data, whereas domain experts remain critical for methodological guidance and biological synthesis across analyses. Together, our results delineate the current potential and boundaries of agentic AI in computational biology, and establish a framework for evaluating AI systems designed to support biological discovery.

Identifiers

PMID42327254
PMCPMC13278126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.